The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shares of Rigel Pharmaceuticals RIGL have rallied 76.7% in the past three months. This stock price rally can be attributed to growing investor confidence regarding the strong growth of the company’s ...

- Rigel's Phase 3 trial in patients with wAIHA has enrolled 80 patients - Rigel's Phase 3 trial in high-risk hospitalized patients with COVID-19 has enrolled ~150 patients - Fostamatinib selected for ...

SOUTH SAN FRANCISCO, Calif., March 11, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the completion of patient enrollment in a multi-center Phase 2 clinical trial to ...

(RTTNews) - Shares of Rigel Pharmaceuticals, Inc. (RIGL) are slipping over 11% in extended session on Monday after the company said it has received guidance from the U.S. Food and Drug ...

Rigel Pharmaceuticals' strategic acquisitions of GAVRETO and REZLIDHIA, along with strong TAVALISSE sales, position the company for significant growth and potential profitability. Despite historical ...

Rigel Pharmaceuticals RIGL is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 ...

Rigel's Q2 results were outstanding, with revenue nearly doubling and net income surging, driven by strong commercial momentum for TAVALISSE, GAVRETO, and REZLIDHIA. Management raised 2025 guidance, ...

SOUTH SAN FRANCISCO, Calif., April 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market close ...

Patients with acute myeloid leukemia (AML) with the isocitrate dehydrogenase-1 genetic mutation now have a second treatment option with Rigel's Rezlidhia. It joins Servier's Tibsovo, which was ...

Shares of Rigel Pharmaceuticals (RIGL-1.51%) recently popped after the company announced a collaboration deal with one of America's largest drugmakers, Eli Lilly (LLY-2.33%). Despite more than ...